Trials Sponsors Conditions Drugs Pricing

Conditions

Biliary Tract Neoplasms Colorectal Cancer Digestive Cancer Esophageal Squamous Cell Carcinoma Gastric Cancer Gastrointestinal Stromal Tumors Neuroendocrine Tumors Pancreatic Cancer Unknown Primary Cancer

Keywords

Umbrella StudyNext Generation Sequence

Outcome Measures

Primary Outcomes (1)

Objective response rate (ORR) of patients receiving targeted agent
Objective response rate (ORR) per RECIST 1.1 criteria according to investigators assessment
up to 2 years

Secondary Outcomes (5)

Proportion of patients with intervening genomic variation
up to 2 years
Progression Free Survival (PFS) of patients receiving targeted agent
up to 2 years

Study Arms (2)

Matched Targeted Agent

EXPERIMENTAL

Matched Targeted Agent

Drug: FGFR Inhibitor, IDH1 Inhibitor, HER2 Inhibitor, PARP Inhibitor, BRAF Inhibitor, MEK Inhibitor, ICIs, EGFR-TKIs, NTRK-TKI, and et. al.

Unmatched Therapy

ACTIVE COMPARATOR

Unmatched Therapy

Drug: Other Therapy

Interventions

FGFR Inhibitor, IDH1 Inhibitor, HER2 Inhibitor, PARP Inhibitor, BRAF Inhibitor, MEK Inhibitor, ICIs, EGFR-TKIs, NTRK-TKI, and et. al.Drug

According to the treatment dose approved by NMPA/FDA, evaluation will be conducted every 2 cycles until tumor progression or adverse events cannot be tolerated.

Also known as: Targeted Agent

Matched Targeted Agent

Other TherapyDrug

Patients will receive other treatments, including cytotoxic drugs, antiangiogenic drugs, best supportive care, clinical trials of unmatched new drugs, etc..

Eligibility Criteria

Age18 Years+

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

Histologically confirmed recurrent or metastatic malignant tumors of digestive tract, including but not limited to:
Biliary tract cancer (including gallbladder cancer and cholangiocarcinoma)

Sponsors & Collaborators

Hangzhou DIAN Medical Diagnostic Center Co., Ltd., China
Type not reportedcollaborator
Peking University
Otherlead
3D Medicines

Study Sites (1)

Peking University Cancer Hospital

Beijing, Beijing Municipality, 100142, China

MeSH Terms

Conditions

Biliary Tract NeoplasmsStomach NeoplasmsEsophageal Squamous Cell CarcinomaColorectal NeoplasmsGastrointestinal Stromal TumorsPancreatic NeoplasmsNeuroendocrine TumorsNeoplasms, Unknown PrimaryGastrointestinal Neoplasms

Interventions

Poly(ADP-ribose) Polymerase Inhibitors

Condition Hierarchy (Ancestors)

Digestive System NeoplasmsNeoplasms by SiteNeoplasmsBiliary Tract Diseases

Study Officials

Lin Shen, MD
Peking University Cancer Hospital & Institute
PRINCIPAL INVESTIGATOR

Enrollment

600 participants (actual enrollment reported by the registry).

Study Design

Study Type: interventional
Phase: not applicable
Allocation: NON RANDOMIZED
Masking: NONE
Purpose: TREATMENT
Intervention Model: PARALLEL
Sponsor Type: OTHER
Responsible Party: PRINCIPAL INVESTIGATOR
PI Title: Professor

Study Record Dates

First Submitted

September 21, 2020

First Posted

October 12, 2020

Study Start

September 23, 2020

Actual (reported)

Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

First Submitted

Study Start

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (5)

Study Arms (2)

Matched Targeted Agent

Unmatched Therapy

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Intervention Hierarchy (Ancestors)

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

First Submitted

Study Start

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (5)

Study Arms (2)

Matched Targeted Agent

Unmatched Therapy

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Intervention Hierarchy (Ancestors)

Source record

Locations